Chronic arsenic exposure is a worldwide health problem, Although arsenic-induced cancer has been widely studied, comparatively little attention has been paid to arsenic-induced vascular disease. Epidemiological studies have shown that chronic arsenic exposure is associated with increased morbidity and mortality from cardiovascular disease. In addition, studies suggest that susceptibility to arsenic~induced vascular disease may be modified by nutritional factors in addition to genetic factors. Recently, animal models for arsenic-induced atherosclerosis and liver sinusoidal endothelial cell dysfunction have been developed. Initial studies in these models show that arsenic exposure accelerates and exacerbates atherosclerosis in apolipoprotein E-knockout mice. Microarray studies of liver mRNA and micro RNA abundance in mice exposed in utero suggest that a permanent state of stress is induced by the arsenic exposure. Furthermore, the livers of the arsenic~exposed mice have activated pathways involved in immune responses suggesting a pro-hyperinflammatory state. Arsenic exposure of mice after weaning shows a clear dose response in the extent ·of disease exacerbation. In addition, increased inflammation in arterial wall is evident. In response to arsenic-stimulated oxidative signaling, liver sinusQidal endothelium differentiates into a continuom; endothelium that limits nutrient exchange and waste elimination. Data suggest that nicotinamide adenine dinucleotide phosphate oxidase-derived superoxide or its derivatives are essential second messengers in the signaling pathway for arsenic-stimulated vessel remodeling. The recent findings provide future directions for research into the cardiovas~ cular effects of arsenic exposure.
I To whom correspondence should be addressed at Department of Pharmacology & Toxicology. Univer,sity of Louisville, 570 South Preston Street, Suite 221, Lousiville. KY 40202. Fax: (502) 852-2492. E-mail: jcstates@louisville.edu. exposure with development of both cardiovascular disease (CVD) and peripheral vascular disea.se. Earlier epidemiological studies provided ~ighly suggestive but not conclusive data supporting the hypothesis that chronic arsenic exposure causes circulatory disease. In addition, until recently animal models to study arsenic-induced circulatory diseases have not been established. A symposium entitled"Arsenic and Cardiovascu lar Disease" was held at the 47th Annual Meeting of the Society of Toxicology in 2008. This symposium, sponsored by the Metals Specialty Section, addressed recent epidemiological evidence and experimental results in murine models for arsenic-induced disease of the circulatory system.
EPIDEMIOWGICAL EVIDENCE ON ARSENIC EXPOSURE AND VASCULAR DISEASE
Although inorganic arsenic has been classified as a group I carcinogen to humans by the International Agency for Research on Cancer, evidence for causal association of other health effects with arnenic exposure has not been well established. Arsenic is abundant in the earth's crust and can be released into ground water under certain ~onditions. Epidemiological studies in parts of the world with high levels of arsenic (>300 flg/l) in ground water have associated arsenic exposure with elevated risks for an array of CVD, including hypertension (Chen et al., 1995; Rahman et aI., 1999) , carotid atherosclerosis (Wang et ai" 2002) , ischemic heart disease (Hsueh et al., 1998; Tseng et al., 2000) , and vascular disease mortality (Chen et al., 1996) , The distinct association with maitifestations of generalized arterio sclerosis supplies certainty on causality. However, the underlying mechanisms have not been well characterized. large scale prospective studies using appropriate biomarkers may help reveal pathways by which arsenic induces vascular disease.
Importantly, little is known about the associations between low-to-moderate level arsenic exposure via drinking water (<300 flg/l) and CVD (Navas-Acien et al., 2005; Wang et ai" 2007a,b) , Studies in areas such as the United States with low to-moderate exposure showed inconsistent findings (Engel and 313 ARSENIC AND CARDIOVASCULAR DISEASE Smith, 1994; Lewis e/ al., 1999; Meliket e/ al., 2007; Zierold et at., 2004) . The heterogeneity of drinking water resources and the limited exposure range together pose a challenge for epidemiological studies io the United States to have valid long-term arsenic exposure measures at the individual level and a large sample size. In addition~ few studies have assessed the interindividual variability to the cardiovascular effect of arsenic exposure. For weak: to moderately strong associations between environmental exposures and disease outcomes, causal in ference can be strengthened if the data show a stronger effect in a susceptible subgroup of the population (Khoury ef al., 2005) .
Such data may also help risk assessment in the population and provide knowledge about the underlying mechanisms.
Reviews of epidemiological studies on ar:senic and CVD have been published (Navas-Acien e/ aI., 2005; Wang ef al., 2007a) . Below, we discuss recent epidemiological studies on arsenic exposure and biomarkers of CVD and studies on the interindividual susceptibility to the cardiovascular effect of arsenic exposure. The studies on interindividual susceptibility are summarized in Table 1 .
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EPIDEMIOLOGICAL EVIDENCE ON INTERINDIVIDUAL VARIABILITY OF ARSENIC'S CARDIOVASCULAR EFFECT
Nutritional Factors
In. a case-control study in villages of-southwestern Taiwan with high levels of arsenic exposure, with median arsenic concentration io villages ranging from 700 to 930 ~g/l, serum samples of 74 patients with ischemic heart disease and 193 matched ,healthy controls were tested for serum levels of micronutrients (Hsueh et al., 1998) . Multivariate analysis showed a synergistic interaction on arsenic-related ischemic heart disease between duration of consuming well water with arsenic exposure and low serum carotene level. The findings suggest that inadequate carotene intake or other factors contributing to low carotene level may increase the suscepti bility to the cardiovascular effects of arsenic exposure. However, the potential mechanisms involved in the protective action remain to be studied.
More recently, in a cross-sectional study of blood pressure usiog data from 10,910 participants in the Health Effects of Arsenic Longitudioal Study (HEALS) io Bangladesh, there was a positive association between low-to-moderate levels of arsenic exposure from drinking water and high pulse pressure (pulse pressure ::: 55 mmHg) , an iodicator of arterial stiffness which is associated with an increased risk of atherosclerosis (Dart and Kingwell, 2001; Safar ef al., 2003) . The likelihood of high pulse pressure was 1.19-1.39 times greater in subjects with higher well arsenic categories (8.1 40.8, 40.9-91.0, 91.1-176.0, and 176.1'-&1 .0 ~g/l) compared with those io the lowest category «8 ~g/I). In addition, among participants with lower than the average dietary intake level of B vitamins and folate, those with a higher well arsenic concentration were 1.83-1.89 times more likely to have a pulse pressure 2::55 mmHg compared with those in the bottom quiotile of well arsenic concentration «8 ~g/I) (Chen et al., 2oo7a) . Methylation of arsenic, a hypothesized detoxification pathway, requires the conversion of S-adenosylmethionine to S-adenosylhomocysteine, which subsequently fonns homocys teine (Gamble et 01., 2005; Zakharyan and Aposhian. 1999 ).
Higher levels of plasma homocysteine have been associated with high blood pressure (Araki ef al., 1989; Lim and Cassano, 2002) . Because the metabolism of homocysteine requires sufficient levels of vitamin B2, B 12, B6, and folic acid (Selhub, 2002) , arsenic exposure may affect blood pressure through its effect on the formation of S-adenosylhomocysteine and homocysteine, especially in a background of inadequate intake of folate and B v~tamins. The findings indicate that the effect of low-level arsenic exposure on blood pressure is nonlinear and may be more pronounced in persons with lower intake of nutrients related to arsenic metabolism and cardiovascular health, although the exact mechanisms are not clear.
Urinary Arsenic Metabolite Profile
Methylation of inorganic As
ill , which is primarily hepatic, first generates monomethylarsonic acid (MMAv). After the reduction of MMAv to MMAill, a second methylation can occur to generate dimethylarsinic acid (DMA v) (Vahter and Concha, 2001) . A growiog number of studies in experimental model systems indicate that MMAill is more toxic than in organic arsenic or any of the pentavalent intermediates (Ahmad ef al., 1999; Nesnow et al., 2002; Styb10 et al., 2002) . Epi demiological studies also suggest that an increased proportion of MMA in urine is associated with an elevated risk of cancers (Chen ef al., 2003a,b; Hsueb et al., 1997; Pu ef al., 2007; Yu et al., 2000) and arsenic-related skin lesions (Ahsan ef al., 2007) . Evidence of the effect of arsenic metabolism on CVD risk is limited. In a case-control study of hypertension con ducted in southwestern Taiwan with high levels of arsenic exposure (median in villages from 700 to 930 ~g/I), hyper tensive cases had higher percentages of MMA v and a lower ratio of DMA v divided by MMA v than those without hyper tension . However, study participants were exposed to arsenic 2-3 decades ago, and those with a high level of arsenic exposure in the past had a higher hypertension irrespective of differences in the composition of urinary arsenic metabolites. Studies in populations with current exposure at low-to-moderate levels are needed to assess whether CVD risk differs by levels of arsenic methylation capacity.
S-transferase PI (GSTP1) (Wang et al., 2007b; Wu et al., 2006) . The high arsenic exposure group (>50 ~g/l) with one or two variant genotypes of GSTP 1 had an increased risk of carotid atherosclerosis showing an odds ratio of 2.8 compared with those with wild-type alleles.
EPIDEMIOWGICAL EVIDENCE ON ARSENIC EXPOSURE AND ENDOTIiELIAL DYSFUNCTION
Circulating markers of systemic inflammation and endothelial dysfunction such ali soluble intercellular adhesion molecule-l (sICAM-I) and soluble vascular adhesion molecule-I (sVCAM-I) are predictive for CVD (Blankenberg et ai., 2001; Hwang et aI., 1997; Ridker et al., 1998 Ridker et al., , 2000 . In a subgroup of 115 individuals with arsenic-related skin lesions in Bangladesh, ther,e was a positive association of urinary arsenic and well arsenic concentration with plasma levels of sICAM-I and sVCAM-I (Chen et al., 2007b) . The positive associations of well arsenic with plasma sVCAM-I and sICAM-I suggest a potential pathway underlying the mechanism of action oflong-tenn arsenic exposure in the development of CVD. However, all the participants had skin lesions and were exposed to moderate levels of arsenic exposure (median exposure 230 ~g/1). Future large studies are required to study the associations of low-level arsenic exposure with markers of vascular inflammation and endothelial dysfunction in healthy persons.
Microalbuminuria, a marker of glomerular hyperfiltration, has been correlated with and may be a manifestation of impaired endothelial function (Paisley et al .. 2003; Stehouwer et aI., 2004) . Impairment of endothelial function is recognized as one of the initial mechanisms that lead to atherosclerosis (Davignon and Ganz, 2004 
ARSENIC EXPOSURE EXACERBATES ATHEROSCLEROSIS IN APOE-KNOCKOUT MICE.
Atherosclerosis is an intricate disease. Primary events consist of fatty streak fonnation under the subendothelial space of Several epidemiological studies suggest exposure to corre lates with endothelial dysfunction and increased incidence of atherosclerosis. However, very little is known about the biochemical mechanisms by which arsenic exerts its proathero genic effects. Genetically altered mice are preferred models to study atherogenesis (Table 2 ). Due to the high levels of high density lipoproteins, wild-type mice are resistant to atheroscle rosis. However, disruption of cholesterol transport by genetic deletion of apolipoprotein E (ApoE) or low-density lipoprotein receptor (LDLr) or overexpression of apoB results· in discernible increase in very low density lipoproteins (VLDL) and/or LDL cholesterol and in atherosclerotic lesion formation throughout the aortic tree that resembles -human disease. Increased accumulation of arsenic in the vessel wall and increased atherosclerotic lesion formation were observed in the aorta of female ApoE-knockout mice given water containing 20 or 100· mg/l sodium arsenite for 24 weeks (Simeonova ef aI., 2003) . Increased lesion fonnation was also observed in the innominate arteries in adult ApoE/LDLr double knockout mice fed sodium arsenite (133 mg/!) for 18 weeks (Bunderson et a!., 2004) . Data presented at the symposium showed that early life arsenic exposure (starting at 3 weeks of age) to (I-50 mg/! arsenic in drinking waler) resulted in macrophage rich lesions in the aortic sinus and the aortic arch in ApoE knockout mice at 10 and 16 weeks of age, without increasing plasma cholesterol. Exposure of adult mice (starting at 12 weeks old) to arsenic for 24 weeks resulted in advanced lesion fonnanon in the aortic sinus, the aortic arch, and the abdominal aorta. Characterization ofthese lesions illustrated increased macrophage accumulation and fibrosis in arsenic-exposed mice as compared to water-fed controls. Temporal studies show~ that exposure to arsenic starting at age 3 weeks accelerated. lesion fonnation at 10, 16, and 36 weeks of age.
ARSENIC EXPOSURE INCREASES OXIDATIVE STRESS IN VASCULAR LESIONS
Studies in experimental animals have shown that oxidized lipids are present in all stages of atherogenesis, and immunization of experimental animals with the protein adducts of the products of-LDL oxidation decreases atherosClerotic lesion formation (George ef ai., 1998; Zhou ef ai., 2001) .
Oxidized lipids· generate several bioactive molecules (e.g., ROS, peroxides, and isoprostanes), of which aldehydes are the major end products (Esterbauer ef af., 1991). Malondialdehyde (MDA) and 4-hydroxY-frans-2-nonenal (HNE) are the most abundant saturated and unsaturated aldehydes generated from the oxidation ofLDL (Esterbauer ef af., 1991) . Protein adducts of MDA and HNE have been detected in atherosclerotic lesions of experimental animals and humans (Jurgens ef aI., 1993; Palinski ef ai., 1989; Rosenfeld and Ross, 1990) . Data presented at the symposium illustrated that lesions in arsenic exposed mice showed increased accumulation of protein adducts of MDA and HNE both in early and in advanced lesions. Increased levels of free MDA and HNE were also detecled in the plasma of -As-exposed mice. Arsenic has also been shown to induce the expression of aldose reductase (Lau et al., 2004) , an enzyme which is an efficient catalyst for the reduction of lipid derived aldehydes (Srivastava ef af., 1998a (Srivastava ef af., ,b, 1999 and is the major aldehyde-metabolizing enzyme in the cardiovascular cells (Srivastava ef af., 2001 (Srivastava ef af., , 2004 . Additionally, several studies have shown that unsaturated lipid aldehydes and arsenic are also efficiently metabolized by GSTs (Chiou ef af., 1997; Yang ef af., 2008). As indicated above, a recent study shows that occurrence of carotid atherosclerosis is significantly associated with genetic polymorphi~m of GSTP1, an enzyme involved in arsenic metabolism (Wang ef af., 2007b) . Since lipid aldehydes are highly reactive and can increase monocyte adhesion, cytokine production, and lipid uptake by scavenger receptorn, it is conceivable that excessive generation of these aldehydes or decreased detoxification upon arsenic exposure exacerbates atherosclerotic lesion formation.
ARSENIC EXPOSURE INCREASES INFLAMMATION IN VASCULAR LESIONS
Cumulative evidence from a large number of studies indicates that inflammation plays a pivotal role in atherosclerotic plaque fonnation. Vascular cells including endothelial cells, macro phages/monocytes, and smooth muscle cells generate chemo ldnes and proinflar:nmatory cytokines including monocyte chemoattractant protein-I (MCP-I), interleukin-6 (1L-6), and tumor necrosis factor Cl. MCP-l and IL-6 are abundant in atherosclerotic lesions, and genetic deletion of these chemoldnes and cytokines in mice decreases atherosclerotic lesion fonnation (Gu ef af., 1998; Schieffer ef af., 2004) . Recently, it has been shown that in vitro sodium arsenite induces the expression of MCP-l and IL-6 in vascular smooth muscle cells (Lee et a/., 2005) . Data presented at the symposium showed increased expression of MCP-l and IL-6 in vascular lesions in As-exposed mice. These observations are consistent with studies illustrating increased expression of circulating lymphocyte MCP-I mRNA and plasma MCP-l concentration in humans exposed to arsenic (Wu el af" 2003) . Recent studies suggest that humans carrying two risk genotypes of ApoE and Mep1 and exposed to drinking water containing >10 Jlg/l have >10-fold risk of carotid atherosclerosis (Hsieh ef ai" 2008) . Together, these observa tions suggest that As-induced inflammation could be an important risk factor for atherosclerosis.
ARSENIC INDUCES ENDOPLASMIC RETICULUM STRESS AND UNFOLDED PROTEIN RESPONSE
Recent studies have suggested that endoplasmic reticulum (ER) stress and subsequent unfolded prolein response (UPR) could be involved in oxidized lipid-induced inflammation.
Gene array analysis (Gargalovic ef ai" 2006) showed that in vitro oxidized lipids induce the expression of several UPR responsive genes in endothelial cells, and activation of UPR occurs in atherosclerotic plaques (Zhou et al., 2005) . Data presented at the symposium showed that in vitro sodium arsenite induces the expression of several ER chaperones including 78-kDa glucose-regulated protein, homocysteine induced endoplasmic reticulum protein, and Calnexin that stabilize protein folding in vascular endothelial cells. Accu mulation of misfolded proteins in the ER activates tJuee ER resident transmembrane proteins, inositol~requiring kinase, activating transcription factor (ATF) 6, and protein kinase like ER kinase (PERK), which then trigger the UPR for cell (Du et 01.,2006; Kim et al., 2008; Roybal et al., 2005; Zhang et al., 2007) . In retinal pigment epithelial cells, arsenic also increased the expression of vascular endothelial growth factor (VEGF). Arsenite-induced VEGF expression was markedly decreased in a dominant-negative A1F4 mutant and A1F4-deficient murine embryonic fibroblast cells. N-acety1cysteine, a potent antioxidant thiol, abolished arsenite-induced UPR and induction of VEGF (Roybal.et al., 2004) . Alternatively, As-induced ER stress could be mediated by homocysteine. As discussed above, methylation of ingested inorganic arsenic to MMA and DMA results in the fonnation of homocysteine (Gamble et al., 2005; Zakharyan and Aposhian, 1999) , a potent inducer of ER stress, endothelial activation, inflammation, and cell proliferation (Austin et al., 2004) .
Increased plasma homocysteine is a risk factor for atheroscle rosis. Recently, it has been shown that the risk of atherosclerosis is increased by more than fivefold in individuals with high plasma homocysteine level (> 12.7mM) and high ·MMA (> 16.5%) concentration in the urine (WU et al., 2006) .
Collectively, proatherogenic affects of arsenic could be attributed at least in part to increased oxidative stress, ER stress, and vascular inflammation.
IN UTERO ARSENIC EXPOSURE
The first evidence that in utero arsenic exposure could cause arterial disease was in reports of myocardial infarction in infants whose mothers consumed water with high levels of arsenic in Antofogasta region of Chile (Rosenberg, 1973 (Rosenberg, , 1974 . These infants were part of a cohort of exposed people which also exhibits increased pulmonary disease (Smith et al., 2006) and CVD (Yuan et al., 2007) (Srivastava et al., 2007) . This study showed that administration of drinking water containing arsenic as sodium arsenite caused early onset of atherosclerosis in "10-week-old male offspring and more severe disease in 16 week-o.ld male offspring maintained on nonna! chow. Plasma cholesterol and phospholipids were unaltered, but significant reductions in plasma triglycerides were observed. In addition, an impaired vasorelaxation response was demonstrated in lO-week-old mice that had been exposed to arsenic in utero.
These results established an experimental model in which mechanistic studies can be perfonned.
It is now well understood that atherosclerosis is a multifacto rial disease process. More recent work also indicates that atherosclerosis may also be a multiorgan disease, with disease modifying risks being derived from distal sites. Indeed, underlying liver disease has been shown to be a risk factor for developing atherosclerosis in humans (Brea et al., 2005; Targhet et al., 2004) and is independent of other risks associated with chronic liver diseases (e.g., metabolic syodrome) (Targher et 01., 2006) . Whereas the mechanisms by which liver disease mo dulates atherosclerosis are cinrently poorly understood, reason able working hypotheses exist. Firs~ it is proposed that systemic oxidative stress and inflammation that occur during liver disease (Haukeland et aI., 2006; Kugelmas et al., 2003) contribute to atherogenesis; this hypothesis is supported by the observation that the risk of atherogenesis increases with severity of hepatic inflammation (Targher et aI., 2006) . Second, abnonnal lipid metabolism caused by underlying liver disease could contribute to atherogenesis; indeed, hepatic steatosis is associated with oveI]lroduction of VLDL in humans (Adiels et al., 2006 ).
Furthennore, atherosclerosis shows a clear correlation with
nonalcoholic fatty liver disease (NAFLD) and circulating markers of liver damage/disease associated with metabolic syndrome (Hanley et al., 2005; Schindhelm et 01.,2007; Targher 2007; Targher et al., 2006; Volzke et al., 2005) . Whereas most of the studies -in humans have been perfonned with NAFLD, we propose that there are parallels between this disease and arsenic toxicity. For example, arsenic is known to cause liver damage in humans (Guha Mazumder, 2001 ) and animal models (Santra et aI., 2000) with histological lesions in the latter analogous to those observed in advanced NAFLD. Thus, inflammation can be a cause or a consequence of liver disease. ApoE-knockout mice are constitutively hyperlipidemic, but the source of inflammation in the arsenic-exposed animals is not obvious.
Chronic arsenic exposure in adults has been associated with liver disease, notably steatosis, portal hypertension, fibrosis, and cirrhosis (Guha Mazumder, 2001 ). Thus, arsenic clearly is deleterious to liver. It is likely that in utero arsenic exposure affects liver deVelopment predisposing to disease. Others have. demonstrated the induction of cancer in two strains of mice transplacentally exposed to arsenic (Waalkes et al., 2003 ARSENIC AND CARDIOVASCULAR DISEASE 2006). A common feature in the transplacental arsenic ex posure model of As-induced carcinogenesis is the induction of hepatocellular cancer. Microarray studies of liver gene ex pression in these mice indicated alterations in the expression of genes related to estrogen receptor alpha (ERCI) function that could contribute to the development of hepatocellular cancer in the arsenic-exposed mice . These gene ex pression changes were correlated with alterations in DNA methylation patterns in ERa (Waalkes.et al., 2004) , suggesting that in utero arsenic exposure caused epigenetic changes in liver. Recently. an epidemiological study of the Chilean cohort with early life arsenic. exposure showed an approximately 10-fold increase in relative risk for childhood liver cancer incidence in the exposed population (Liaw et.a!.. 2008) . Thus. early life arsenic exposure clearly alters liver development and predisposes to chronic disease.
Kupffer cells are specialized macrophages that are resident in liver. These cells are a major source of cytokines that a~e secreted in response to infections and to hepatotoxic insult (Fainboim ef al., 2007; Roberts et al., 2007) . Thus, one possibility is that liver is the source of inflanunatory cytokines leading to initiation of vascular disease in .arsenic-exposed ApoE-knockout mice. Studies discussed in the symposium addressed the .hypothesis that the in utero arsenic exposure altered liver development making the livers of exposed mice hyperresponsive to inflammatory stimuli.
Micro-RNAs (miRNAs) are small RNAs that regulate gene expression and are thought to playa critical role in modulating embryonic and fetal development (Hornstein and Shomron, 2006) . Alterations in miRNAs during development are associated with alterations in histone modification and DNA methylation. Thus, miRNAs modulate epigenetic control of gene expression. If transplacental arsenic exposure is altering epigenetics in liver, then one would expect that alterations in miRNA expression would be observed in arsenic-exposed animals. Results of microarray experiments conducted to evaluate changes in liver mRNA and miRNA expression in arsenic-exposed ApoE-knockout mice on the first day of life (PND1) and at 10 weeks of age (PND70) were discussed in the symposium presentation. A 51-gene signature of mRNAs with altered expression at both PND 1 and PND70 suggested that pathways associated with inflammatory responses were in duced in arsenic-exposed mice. Further analyses of total mRNA and miRNA expression changes indicated that de velopment.al trajectory was altered by arsenic exposure. Furthennore, genes common to putative targets of changed miRNAs and changed mRNAs also supported induction of pathways associated with inflammatory responses in 10-:week old arsenic-exposed ApoE-knockout mice. Thus, the data suggest that the in utero arsenic exposure altered the liver developmental program in such a way as to prime the liver to hyperrespond to an inflammatory signal.
A recent study of global gene expression changes in neonatal chord blood lymphocytes reported that stress response and inflammatory. response networks were activated in human newborns exposed to .arsemc in utero (Fry et ai., 2007) . This clear correlation between human and mouse studies support the hypothesis that in utero arsenic exposure alters developmental programming and induces a proinfiammatofy state. Thus, both epidemiological data and experimental data clearly show that in utero exposure to high levels of arsenic in drinking water induces vascular disease in humans and mice. The challenge for the future is to determine the impact on vascular disease of exposure. to arsenic at lower levels. Elucidation of potential interacting factors such as hyperlipidemia will provide much needed information related to determining the impact of moderate-level arsenic exposure on increased mortality due to CVD in the United States and other areas of the world with low-to-moderate arsenic levels in drinking water.
ARSENIC STIMULATION OF VASCULAR REDOX BIGNALING
As discussed above, exposure to arsenic in drinking water increases risk for a number of CVDs including acute myocardial infarctions (Yuan et aI., 2007) , cardiac ischemic disease (Wang ef aI., 2007a) , peripheral .vascular disease (Wang ef al., 2007a) , systemic hypertension Kwok et al., 2007) , and liver portal hypertension (Mazumder, 2005) . The finding by Chen ef al. of increased pulse pressure in individuals exposed to low-to-moderate levels of arsenic is consistent with a large body of literature implicating the cells in the blood vessel walls as primary targets of arsenic toxicity. ill general, increased pulse pressure or 'enhanced peripheral resistance in hypertension results from enhanced stiffness and decreased compliance of the vessel wall. These impair:ed. vascular functions are caused by dysregulation of vasomotor function and/or structural remod eling of blood vessels. A major drive for both disrupted sigmiling and remodeling is change in ROS or redox signaling in the both the vascular endot~elia1 and the smooth muscle cells (Lee and Griendling, 2008; Lyle and Griendling, 2006) . NOX enzymes are multimeric protein complexes that produce superoxide by electron transfer from NADPH to molecular oxygen (Lee and Griendling, 2008) . Increased activity of vascular NOX enzymes plays a central role in pathogenic redox signaling in vascular disease and hyperten sion (Lee and Griendling, 2008; Lyle and Griendling, 2006) , and arsenic rapidly stimulates both endothelial (Smith et a!., 2001) and smooth muscle (Lynn ef aI., 2000) NOX enzymes. However, the mechanism through which arsenic stimulates NOX enzyme activity remains unresolved. Previous studies demonstrated that endothelial cell NOX-generated superoxide and hydrogen peroxide levels increase within 5 min of exposure to low J.lM concentrations of arsenite (Barchowsky et al., 1999) and total NOX catalytic capacity remained elevated for 1 h following ex vivo arsenic exposure (Smith 318 STATES ET AL. et al., 2001) . To date, the best evidence that NOX-generated oxidants are critical mediators of the vascular actions of arsenic comes from studies investigating mechanisms for arsenic promoted remodeling of the liver sinusoidal endothelial cells (LSECs). Exposure of mice to a moderate level of arsenic (250 flg/l) in their drinking water promoted a time-dependent closure of the LSEC fenestrations as they underwent differentiation into a nonnal endothelium in a process called capi11arization (Straub et al., 2007a,b) . This effect was dose dependent with a threshold for loss of fenestrations occurring after 2-week exposures to 10 flg/1 of "",enite (Straub et al., 2008) . Maximal defenestration occurred following exposure to 1 00 ~lg/l,' and these exposures were also associated with increased protein nitration in the liver sinusoids and loss of scavenging of modified albumin across the . liver. Capillarization and protein nitration did not occur in p47 phox null mice exposed to 100 Ilg/l of arsenite for 2 weeks (Straub ef al., 2008) . Deletion of p47 pho X, the cytosolic re gulatory subunit of multiple fonns of NOXs, makes mice resistant to endogenous ligand-induced hypertension and blunl~ the increase in ROS production (Lee and Griendling, 2008) . Further, disruption of the interaction between p47phox and gp91 of Nox2-based oxidase in primary isolates of LSEC prevented not only ex vivo arsenite-stimulated oxidant generation but also defenestration and modified albumin uptake (Straub et al., 2008) . Finally, ex vivo addition of 50flM hydrogen peroxide to the LSEC was sufficient to promote defenestration. These data suggest that NOX-derived superoxide and subsequent hydrogen peroxide fonnation provides' essential secOI;td messengers in the signaling pathway for arsenic-stimulated vessel remodeling.
The rapid increase in NOX activity and ROS second messengers suggested that the actions of arsenic were_ not random and that they might involve a signal amplification cascade. In support of this hypothesis, arsenite mobilizes another essential subunit of the NOX complex, Rae 1-GTPase, to the endothelial cell membrane within 5 min of exposure (Smith et at., 2001) . Exposing mice to arsenite also causes-sustained localization of Rac1 to the LSEC membranes in vivo (Straub et al., 2007a) , and inhibiting or eliminating endothelial cell Racl-GTPase inhibits amenic-stimulated NOX activity (Qian et al., 2005; Smith et al., 2001) . In addition to activating NOX complexes, Rac1 is essential for endothelial and smooth muscle cell migration that is required for both angiogenesis and vessel remodeling (Brown et.al., 2006) . Thus, activation of Rac! may represent another key regulatory step in the signal amplification scheme for arsenic-stimulated vascular cell dysfunction.
Endogenous hypertensive peptides, such as angiotensin n or endothelin-1, interact with cognate G-protein coupled receptors (GPCR) to initiate Rac!-GTPase-<lependent superoxide gener ation by NOX enzymes (Lee and Griendling, 2008) . More specifically, it· is the Gcti-coupled receptor subtypes for these ligands that amplify signals to increase Rae 1-GTPase activity and stimulate NOX (Brown et al., 2006) . To determine whether arsenite also targeted a GPCR as an initial step in NOX activation, human microvascular endothelial cells were preincu bated with Goo-selective inhibitor, Pertussis toxin (Ptx). Relative to the effects of arsenite on untreated cells, Ptx prevented arsenite from activating Racl-GTPase activity and increasing downstream changes in angiogenic and inflammatory gene expression. However, neither Ptx nor a direct inhibitor of Rael prevented arsenite from stimulating an adaptive or stress responsive increase in heme oxygenase-l mRNA levels.
The majority of reports in the literature and the data presented support the vascular NOX system as being critical in the molecular pathology of arsenic-related vascular disease. Data from the p47 phOK null mice and recent epidemiological studies (Hsueh et al., 2005) provide support that NOX activity contributes to both vascular dysfunction and remodeling. The novel data presented here further define the signaling pathways that contribute to these conditions by demonstrating that arsenic interactions with vascular cells are amplified through a signaling cascade that requires both GTPase and oxidase generated second messengers. Figure 1 presents a hypothetical scheme linking action of arsenite on a Ga.i-coupled receptor to downstream NOX activation. Generation of excess reactive oxygen second messengers is a primary mechanism of hypertension and vascular disease that diminishes relaxation and promotes inappropriate signaling' for proliferation and remodeling that stiffens or occludes blood vessels (Lee and Griendling, 2008; Lyle and Griendling, 2006 (Hirano et al., 2004) . It will be intriguing 10 detennine whether the methylated metabolites also require GPCR receptors to produce cellular effects and whether dif ferences in sensitivity to inorganic and organic species relate to differences in receptor affinities or actions on different receptors.
SUMMARY AND FUTURE DIRECTIONS
In summary, the presentations in this 8ymposium discussed current evidence for the association between arsenic and vascular disease from epidemiological studies and the un derlying mechanisms from animal/experimental studies.
The epidemiological literature to dale suggesls that the cardiovascular effects of arsenic exposure are modified by nutritional factors, genetics, and arsenic metabolism capacity. In particular, the data suggest an important role played by factors related to oxidative stress and vascular inflammation. However, most of the existing epidemiological studies were conducted in populations with high levels of arsenic exposure and with a relatively small sample size. The challenges for future epidemiological studies of arsenic and vascular disease include (I) longitudinal studies to capture long-tenn arsenic exposure at the individual level, (2) use of reliable biomarkers, (3) inclusion of persons with low-to-moderate exposUre, and (4) use of a comprehensive genomic approach to _evaluate genetic susceptibility.
Findings from mechanistic studies indicate that arsenic causes inflammation in vascular tissues and activates oxidative signaling. Observed endothelial cell dysfunction is likely a consequence of direct effects on -the vascular cells and indirect effects on the liver vasculature caused by arsenic exposure-promoted inflammation, disrupted lipid metabolism, and increased lipid oxidation. Thus, the liver appears to be a major site of arsenic action from the standpoint of both generation of potentially more toxic metabolites and sensitivity to toxic -actions on its unique vasculature. In addition to the metabolic changes, epigenetic changes in liver also are a consequence of chronic arsenic exposure. The epigenetic changes appear to result in a chronic state of cellular stress with a predisposition to heightened inflammatory responses. These changes can result in overt liver disease and also likely play a role in development of systemic vascular disease. The role of nutrition in modulating the vascular disease manifestations of chronic arsenic exposure is likely related to modification of arsenic's impact on liver function. Clearly, more studies are needed to elucidate the interactions of arsenic exposure, liver function, nutrition, and' vascular disease.
Since CVD constitutes about one-third of total mortality in the world and a!senic exposure at low-to-moderate levels is more prevalent, a small increased risk associated with arsenic exposure would translate into large numbers of excess deaths and would be of wide public health significance. Additional large epidemiological and mechanistic studies are needed to identify susceptibility factors and underlying mechanisms especially for low-level exposure.
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